In the possible event of a pandemic, the UK has secured 5 million doses of an H5 influenza vaccine to stay one step ahead of the avian influenza virus.
Ben Davison, NHS Digital’s Executive Director for Product Development, explains how the coronavirus pandemic prompts a surge in the number of people using NHS tech in 2020.
Here, a leading clinical negligence specialist warns the UK may be heading for a “perfect storm” of diabetes complications, due to delayed COVID-19 referrals.
Zillah Moore, Director at Tunstall Healthcare, discusses the role of technology-enabled care services and remote patient monitoring in reducing delayed discharge from hospitals and providing much-needed assistance to the NHS.
Brian Holden, Global Director of Financial Services at SAS UK & Ireland, explores the potential of the UK Government managing debt collection in the wake of the pandemic.
Dr Deborah Lee, Dr Fox Online Pharmacy, discusses how the COVID-19 pandemic can affect the use of the pill, the contraceptive patch and the vaginal ring.
George Atalla, EY Global Government & Infrastructure Leader, explores the effect that COVID-19 has had on the use of data and technology in healthcare.
Experts from the International Agency for Research on Cancer and the University of Molise chart the impact of the COVID-19 pandemic on cancer treatment.
![Figure 1. Systemic immune responses elicited by oral dmLT-saponin combinations compared to injected vaccines (A) Cryo-electron microscopy (cryo-EM) image of the dmLT and saponin formulation demonstrating the formation of acid-stable micelle particles upon the addition of saponin to dmLT. (B) Preclinical evaluation of systemic serum IgG and IgA antibody responses following prime/boost vaccination. Antibody levels against the microbial protein antigen included in the vaccination were assessed two weeks post-final vaccination in immunized mice. Groups were stratified by vaccination route (intramuscular [IM] or sublingual [SL]) and adjuvant formulation (dmLT [D] and/or saponin [S]). Comparisons with unvaccinated controls (white bars) are shown. Statistical significance between groups is indicated (*P < 0.05), with the SL D+S group achieving the best IgG and IgA responses to vaccine antigen.](https://www.openaccessgovernment.org/wp-content/uploads/2025/01/Figure-01.jpg)
